Keyword: Brineura

BioMarin and Invitae are expanding their free genetic testing program for children with seizures with new partners and a wider patient age range.

BioMarin and NICE have been negotiating for a year, but that hasn’t helped the company secure reimbursement for its Batten disease drug.

BioMarin knows winning drug names. For the second time, one of its drugs won our #FierceMadness tournament—thanks in large part to BioMarin employees.

First rule of ballot stuffing? To avoid raising red flags, don't overdo it. And that’s exactly what 34,035 #FierceMadness votes for Brineura did.

​​​​​​​The final showdown is set: BioMarin’s Brineura will face off against AstraZeneca’s Imfinzi in the drug name championship for 2018.

We're down to four, folks. The #FierceMadness Final Four field is set after an Elite Eight that featured both blowouts and close calls.

Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.

In what was a fast and furious two-day round of voting, the #FierceMadness drug name tournament field has narrowed to just 16.

Our tournament mirrored the NCAA's this week, with No. 16 Giapreza sending home No. 1 Xiidra.

There's a new medicine atop of pharma's global pricing charts, and it's Spark Therapeutics' Luxturna.